• Publications
  • Influence
G-Protein–Coupled Receptor Mas Is a Physiological Antagonist of the Angiotensin II Type 1 Receptor
Background—We previously identified the G-protein–coupled receptor Mas, encoded by the Mas proto-oncogene, as an endogenous receptor for the heptapeptide angiotensin-(1-7); however, the receptor isExpand
  • 337
  • 20
International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli
The renin angiotensin system (RAS) produced hormone peptides regulate many vital body functions. Dysfunctional signaling by receptors for RAS peptides leads to pathologic states. Nearly half ofExpand
  • 140
  • 11
  • PDF
Angiotensin IV Activates the Nuclear Transcription Factor-&kgr;B and Related Proinflammatory Genes in Vascular Smooth Muscle Cells
Inflammation is a key event in the development of atherosclerosis. Nuclear factor-&kgr;B (NF-&kgr;B) is important in the inflammatory response regulation. The effector peptide of the reninExpand
  • 78
  • 4
Involvement of insulin-regulated aminopeptidase in the effects of the renin–angiotensin fragment angiotensin IV: a review
For decades, angiotensin (Ang) II was considered as the end product and the only bioactive peptide of the renin–angiotensin system (RAS). However, later studies revealed biological activity for otherExpand
  • 82
  • 4
Characterization of muscarinic receptors in human, guinea pig and rat lung.
Muscarinic receptor subtypes in human, guinea pig and rat lung tissue were characterized by radioligand binding, and functional studies were carried out on guinea pig and rat tissues. Control bindingExpand
  • 62
  • 3
Metabolism of angiotensin II is required for its in vivo effect on dopamine release in the striatum of the rat
The effect of angiotensin (Ang) IV, an inhibitor of insulin‐regulated aminopeptidase (IRAP), on extracellular dopamine levels in the striatum of freely moving rats was examined using in vivoExpand
  • 57
  • 3
Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism
Drug–receptor interactions are traditionally quantified in terms of affinity and efficacy, but there is increasing awareness that the drug-on-receptor residence time also affects clinicalExpand
  • 61
  • 3
Agonist induction and conformational selection during activation of a G-protein-coupled receptor.
Substitutions of Asn111 of the AT(1) angiotensin receptor and mutations of the corresponding amino acids in other G-protein-coupled receptors (GPCRs) cause constitutive receptor activation. LigandExpand
  • 57
  • 2
Cellular targets for angiotensin II fragments: pharmacological and molecular evidence
Although angiotensin II has long been considered to represent the end product of the renin-angiotensin system (RAS), there is accumulating evidence that it encompasses additional effector peptidesExpand
  • 69
  • 2